6MN7

Cryo-EM structure of BG505.SOSIP.664 in complex with BF520.1 antigen binding fragment

6MN7 の概要

• エントリーDOI: 10.2210/pdb6mn7/pdb
• EMDBエントリー: 9166
• 分子名称: Envelope Glycoprotein gp120, 2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope Glycoprotein gp41, ... (10 entities in total)
• 機能のキーワード: viral protein, complex, broadly neutralizing antibody
• 由来する生物種: Human immunodeficiency virus 1; 詳細
• タンパク質・核酸の鎖数: 9
• 化学式量合計: 325967.90

構造登録者

Williams, J.A.,Lee, K.K.,Overbaugh, J. (登録日: 2018-10-01, 公開日: 2019-03-06, 最終更新日: 2024-11-20)

主引用文献

Simonich, C.A.,Doepker, L.,Ralph, D.,Williams, J.A.,Dhar, A.,Yaffe, Z.,Gentles, L.,Small, C.T.,Oliver, B.,Vigdorovich, V.,Mangala Prasad, V.,Nduati, R.,Sather, D.N.,Lee, K.K.,Matsen Iv, F.A.,Overbaugh, J.
Kappa chain maturation helps drive rapid development of an infant HIV-1 broadly neutralizing antibody lineage.
Nat Commun, 10:2190-2190, 2019

PubMed Abstract: HIV-infected infants develop broadly neutralizing plasma responses with more rapid kinetics than adults, suggesting the ontogeny of infant responses could better inform a path to achievable vaccine targets. Here we reconstruct the developmental lineage of BF520.1, an infant-derived HIV-specific broadly neutralizing antibody (bnAb), using computational methods developed specifically for this purpose. We find that the BF520.1 inferred naive precursor binds HIV Env. We also show that heterologous cross-clade neutralizing activity evolved in the infant within six months of infection and that, ultimately, only 2% SHM is needed to achieve the full breadth of the mature antibody. Mutagenesis and structural analyses reveal that, for this infant bnAb, substitutions in the kappa chain were critical for activity, particularly in CDRL1. Overall, the developmental pathway of this infant antibody includes features distinct from adult antibodies, including several that may be amenable to better vaccine responses.

PubMed: 31097697
DOI: 10.1038/s41467-019-09481-7

実験手法

ELECTRON MICROSCOPY (4.8 Å)